IPO Timeline
Broker Deadline
2025-06-18
Morning deadline
HKEX Deadline
2025-06-18
Noon deadline
Broker Results (T-2)
2025-06-19
Some brokers release in afternoon
Grey Market (T-1)
2025-06-20
Afternoon
HKEX Allotment (T-1)
2025-06-20
Evening
Registrar Allotment (T-1)
2025-06-20
Evening
Listing Day (T)
2025-06-23
First day of trading
Company Overview
| Stock Name | 药捷安康－Ｂ |
|---|---|
| Stock Code | 02617 |
| Company Full Name | 药捷安康－Ｂ |
| Industry | 醫療保健 |
| Principal Activities | 公司是一家以臨床需求為導向、處于注冊臨床階段的生物制藥公司，專注于發現及開發腫瘤、炎癥及心臟代謝疾病小分子創新療法。 |
| Listing Date | 2025-06-23 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國江蘇省南京市江北新區生物醫藥谷加速器二期9棟3樓 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://www.transthera.com/En/Index/index |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | 18A生物科技 |
|---|---|
| Offer Price | HK$ 13.15 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2025-06-13 to 2025-06-18 |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | No |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 64.0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 40,199,550 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 23.5 |
|---|---|
| First Day Open | HK$ 21.65 |
| First Day Change | 78.71% |
| First Day Volume | 8541000.0 |
| First Day Turnover | 191298000.0 |
Use of Proceeds
| Use of Proceeds | 1、約90.0%或145.2百萬港元將用于為我們的核心產品Tinengotinib正在進行單藥治療CCA的多區域注冊III期臨床試驗提供資金； 2、約10.0%或16.1百萬港元將分配用于我們的一般營運資金及一般公司用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
中信证券（香港）有限公司 CE AAK249
华泰金融控股（香港）有限公司 CE AOK809
Sponsor cum Overall Coordinator (2)
中信里昂证券有限公司 CE AAB893
华泰金融控股（香港）有限公司 CE AOK809
Overall Coordinators (3)
中信里昂证券有限公司 CE AAB893
华泰金融控股（香港）有限公司 CE AOK809
交银国际证券有限公司 CE APJ121
Joint Global Coordinators (3)
中信里昂证券有限公司 CE AAB893
华泰金融控股（香港）有限公司 CE AOK809
交银国际证券有限公司 CE APJ121
Joint Bookrunners (7)
中信里昂证券有限公司 CE AAB893
华泰金融控股（香港）有限公司 CE AOK809
交银国际证券有限公司 CE APJ121
中银国际亚洲有限公司 CE AET863
招银国际融资有限公司 CE AVM940
浦银国际融资有限公司 CE BFZ375
TradeGo Markets Limited CE BRO637
Joint Lead Managers (7)
中信里昂证券有限公司 CE AAB893
华泰金融控股（香港）有限公司 CE AOK809
交银国际证券有限公司 CE APJ121
中银国际亚洲有限公司 CE AET863
招银国际融资有限公司 CE AVM940
浦银国际融资有限公司 CE BFZ375
TradeGo Markets Limited CE BRO637
Capital Market Intermediaries (7)
中信里昂证券有限公司 CE AAB893
华泰金融控股（香港）有限公司 CE AOK809
交银国际证券有限公司 CE APJ121
中银国际亚洲有限公司 CE AET863
招银国际融资有限公司 CE AVM940
浦银国际融资有限公司 CE BFZ375
TradeGo Markets Limited CE BRO637
Service Providers
| Role | Institution |
|---|---|
| Legal Advisor to Company |
美迈斯律师事务所 嘉源律师事务所 |
| Legal Advisor to Sponsors/Underwriters |
盛德律师事务所 竞天公诚律师事务所 |
| Auditor and Reporting Accountant | 安永会计师事务所 |
| Industry Advisor | 弗若斯特沙利文（北京）咨询有限公司上海分公司 |
| Receiving Banks |
招商永隆银行有限公司 中国银行（香港）有限公司 |
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 华盛敦行有限公司 | 21,592,300 HKD | — | 10.75% | — | 6 months | 2025-12-23 |
| 2 | 江北医药科技(香港)有限公司 | 75,487,575 HKD | — | 37.57% | — | 6 months | 2025-12-23 |
| 3 | 康方生物科技(开曼)有限公司 | 9,895,375 HKD | — | 4.92% | — | 6 months | 2025-12-23 |
| 4 | 科瓴安(香港)科技有限公司 | 10,750,125 HKD | — | 5.35% | — | 6 months | 2025-12-23 |
| 5 | 药石地平线资本有限公司 | 10,802,725 HKD | — | 5.38% | — | 6 months | 2025-12-23 |
Directors & Management
| Chairman | 吳永謙 |
|---|---|
| Company Secretary | 馮潔,黃荻 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 南京益鏷生物科技合伙企業(有限合伙)(13.79%),吳永謙(12.06%),南京吉旻瑞生物科技合伙企業(有限合伙)(7.13%),基科發展有限公司(6.96%),先進制造產業投資基金二期(有限合伙)(6.12%) |
|---|
IPO Timeline
